• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

产超广谱β-内酰胺酶所致慢性前列腺炎口服磷霉素治疗1例报告

Chronic prostatitis caused by extended-spectrum β-lactamase-producing managed using oral fosfomycin-A case report.

作者信息

Almeida Francisco, Santos Silva André, Silva Pinto André, Sarmento António

机构信息

Faculty of Medicine of the University of Porto, Infectious Diseases department, Centro Hospitalar de São João, Porto, Portugal.

出版信息

IDCases. 2019 Jan 24;15:e00493. doi: 10.1016/j.idcr.2019.e00493. eCollection 2019.

DOI:10.1016/j.idcr.2019.e00493
PMID:30766796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6360601/
Abstract

Prostatitis is a clinical condition of difficult management and with limited antimicrobial options, especially in the setting of antimicrobial resistance. Recurrences are frequent and can be severe. Limited reports support the use of fosfomycin for chronic prostatitis by ESBL-producing bacteria. We reported a case of a patient with chronic prostatitis caused by ESBL-producing with several relapses after prolonged periods of treatment with broad-spectrum intravenous antibiotic therapy and with recurring urinary symptoms after transuretheral prostatic resection. After resolution of the last infection, we performed a long-term eradication antimicrobial treatment with 3 g of fosfomycin once daily, altered to 3 g every 48 h after 10 days due to diarrhea (which resolved with the dose change). After three months with this dosage, fosfomycin was switched to a once-weekly regimen which was maintained for further 9 months. After 9 months of follow-up without antimicrobial treatment, the patient has remained free of urinary symptoms. Experience with fosfomycin for chronic prostatitis caused by ESBL-producing is limited to three case reports and two case series. Intraprostatic measurements have shown adequate penetration of fosfomycin into prostatic tissue. Accordingly, our report suggests that fosfomycin can be used as eradication therapy in a patient with a prior history of chronic prostatitis by ESBL-producing bacteria with recurring urinary infections after surgical treatment.

摘要

前列腺炎是一种临床治疗困难且抗菌选择有限的疾病,尤其是在存在抗菌药物耐药的情况下。复发频繁且可能很严重。仅有有限的报告支持使用磷霉素治疗产超广谱β-内酰胺酶(ESBL)细菌引起的慢性前列腺炎。我们报告了一例慢性前列腺炎患者,该患者由产ESBL细菌引起,在接受长时间广谱静脉抗生素治疗后多次复发,经尿道前列腺切除术后仍有反复的泌尿系统症状。在最后一次感染得到缓解后,我们采用每日一次3克磷霉素进行长期根除性抗菌治疗,10天后因腹泻(随着剂量改变而缓解)改为每48小时3克。采用此剂量治疗三个月后,将磷霉素改为每周一次的方案,并维持9个月。在未进行抗菌治疗的9个月随访期后,该患者一直没有泌尿系统症状。关于磷霉素治疗产ESBL细菌引起的慢性前列腺炎的经验仅限于三份病例报告和两个病例系列。前列腺内测量显示磷霉素能充分渗透到前列腺组织中。因此,我们的报告表明,对于有产ESBL细菌引起的慢性前列腺炎病史且手术后反复发生泌尿系统感染的患者,磷霉素可作为根除治疗药物。

相似文献

1
Chronic prostatitis caused by extended-spectrum β-lactamase-producing managed using oral fosfomycin-A case report.产超广谱β-内酰胺酶所致慢性前列腺炎口服磷霉素治疗1例报告
IDCases. 2019 Jan 24;15:e00493. doi: 10.1016/j.idcr.2019.e00493. eCollection 2019.
2
Persistent extended-spectrum β-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline.磷霉素联合多西环素成功治疗持续性产超广谱β-内酰胺酶大肠埃希菌慢性前列腺炎。
Int J Antimicrob Agents. 2015 Apr;45(4):427-9. doi: 10.1016/j.ijantimicag.2014.12.019. Epub 2015 Jan 20.
3
Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant .口服磷霉素治疗多重耐药菌引起的急慢性细菌性前列腺炎
Can J Infect Dis Med Microbiol. 2018 Jan 30;2018:1404813. doi: 10.1155/2018/1404813. eCollection 2018.
4
Cefoxitin-based antibiotic therapy for extended-spectrum β-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study.头孢西丁为基础的抗生素治疗产超广谱β-内酰胺酶肠杆菌科前列腺炎:一项前瞻性的初步研究。
Int J Antimicrob Agents. 2018 Jun;51(6):836-841. doi: 10.1016/j.ijantimicag.2018.01.008. Epub 2018 May 9.
5
Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study.磷霉素氨丁三醇与 N-乙酰半胱氨酸联合口服治疗治疗困难性慢性细菌性前列腺炎:一项初步研究的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105935. doi: 10.1016/j.ijantimicag.2020.105935. Epub 2020 Mar 8.
6
Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.磷霉素与厄他培南治疗产超广谱β-内酰胺酶尿路感染的门诊或降阶梯治疗比较。
Int J Antimicrob Agents. 2016 Jul;48(1):56-60. doi: 10.1016/j.ijantimicag.2016.04.014. Epub 2016 May 12.
7
Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.中国温州尿路感染中产超广谱β-内酰胺酶大肠埃希菌的药敏情况及耐药机制研究
Int J Antimicrob Agents. 2017 Jul;50(1):29-34. doi: 10.1016/j.ijantimicag.2017.02.010. Epub 2017 Apr 26.
8
Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.台湾一家教学医院中产超广谱β-内酰胺酶的大肠埃希菌和肺炎克雷伯菌对磷霉素和呋喃妥因的药敏性。
J Microbiol Immunol Infect. 2011 Oct;44(5):364-8. doi: 10.1016/j.jmii.2010.08.012. Epub 2011 Jan 20.
9
Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.医疗保健相关尿路感染中产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌的抗菌药敏性:聚焦对磷霉素的敏感性
Int Urol Nephrol. 2015 Jul;47(7):1059-66. doi: 10.1007/s11255-015-1018-9. Epub 2015 May 31.
10
The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.磷霉素对从尿路感染中分离出的产超广谱β-内酰胺酶肠杆菌科细菌的活性:一项为期12年的单中心研究
Microb Drug Resist. 2018 Jun;24(5):607-612. doi: 10.1089/mdr.2017.0097. Epub 2017 Oct 24.

引用本文的文献

1
Fosfomycin for the treatment of patients with bacterial prostatitis: a systematic review.磷霉素治疗细菌性前列腺炎患者:一项系统评价
Eur J Clin Microbiol Infect Dis. 2025 May 23. doi: 10.1007/s10096-025-05173-x.
2
[Microbial etiology of bacterial chronic prostatitis: systematic review].[细菌性慢性前列腺炎的微生物病因学:系统评价]
Rev Esp Quimioter. 2023 Apr;36(2):144-151. doi: 10.37201/req/099.2022. Epub 2023 Jan 9.
3
Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations.口服磷霉素制剂在细菌性前列腺炎中的应用:老药新角色——文献综述与临床考量
Infect Dis Rep. 2022 Aug 18;14(4):621-634. doi: 10.3390/idr14040067.
4
Using the PCR and Blood Agar in Diagnosis of Semen Bacterial Contamination of Fertile and Infertile Men.应用聚合酶链反应和血琼脂培养基诊断有生育能力和不育男性精液细菌污染情况
Rep Biochem Mol Biol. 2021 Oct;10(3):402-411. doi: 10.52547/rbmb.10.3.402.
5
Pharmacological Interventions for Bacterial Prostatitis.细菌性前列腺炎的药物治疗干预措施。
Front Pharmacol. 2020 Apr 30;11:504. doi: 10.3389/fphar.2020.00504. eCollection 2020.

本文引用的文献

1
Raoultella planticola chronic bacterial prostatitis with prostatic calcifications: successful treatment with prolonged fosfomycin therapy.植生拉乌尔菌所致慢性细菌性前列腺炎伴前列腺钙化:延长磷霉素治疗成功治愈
Int J Antimicrob Agents. 2016 May;47(5):414. doi: 10.1016/j.ijantimicag.2016.02.009. Epub 2016 Mar 24.
2
Fosfomycin.磷霉素
Clin Microbiol Rev. 2016 Apr;29(2):321-47. doi: 10.1128/CMR.00068-15.
3
Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis.长期使用磷霉素氨丁三醇口服治疗难治性慢性细菌性前列腺炎
Antimicrob Agents Chemother. 2015 Dec 14;60(3):1854-8. doi: 10.1128/AAC.02611-15.
4
Bacterial prostatitis.细菌性前列腺炎
Curr Opin Infect Dis. 2016 Feb;29(1):86-91. doi: 10.1097/QCO.0000000000000222.
5
Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs.磷霉素治疗前列腺炎:老药新用。
Clin Infect Dis. 2015 Oct 1;61(7):1141-3. doi: 10.1093/cid/civ436. Epub 2015 Jun 10.
6
Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.磷霉素与美罗培南治疗产超广谱β-内酰胺酶大肠埃希菌引起的菌血症性尿路感染(FOREST):一项研究者发起的随机对照试验研究方案
BMJ Open. 2015 Mar 31;5(3):e007363. doi: 10.1136/bmjopen-2014-007363.
7
Persistent extended-spectrum β-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline.磷霉素联合多西环素成功治疗持续性产超广谱β-内酰胺酶大肠埃希菌慢性前列腺炎。
Int J Antimicrob Agents. 2015 Apr;45(4):427-9. doi: 10.1016/j.ijantimicag.2014.12.019. Epub 2015 Jan 20.
8
Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?磷霉素是否是治疗多重耐药革兰氏阴性前列腺炎的潜在替代疗法?
Clin Infect Dis. 2014 Feb;58(4):e101-5. doi: 10.1093/cid/cit704. Epub 2013 Oct 28.
9
The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study.产生物膜细菌对慢性细菌性前列腺炎治疗的影响:一项纵向队列研究的结果
World J Urol. 2014 Jun;32(3):737-42. doi: 10.1007/s00345-013-1145-9. Epub 2013 Aug 6.
10
Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model.磷霉素、替加环素、黏菌素和庆大霉素对异物感染模型中产超广谱β-内酰胺酶大肠埃希菌的活性。
Antimicrob Agents Chemother. 2013 Mar;57(3):1421-7. doi: 10.1128/AAC.01718-12. Epub 2013 Jan 7.